IP Library Granted Patent US 7,700,650
Granted Patent B2
US 7,700,650 · App. 10/239,444 · Granted Apr 20, 2010

Lipoxin analogs and method for the treatment of periodontal disease

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,700,650
App. No.
10/239,444
Granted
Apr 20, 2010
Kind
B2
Abstract

This invention provides new lipoxin analogs, compositions containing these analogs, and methods of using these compounds and compositions for treating and preventing oral inflammation, including gingivitis, periodontitis, and other forms of periodontal disease. The invention also provides for methods of treating and preventing oral inflammation, including gingivitis, periodontitis, and other forms of periodontal disease with compositions containing COX-2 inhibitors. Further, the invention provides methods for preventing systemic diseases beyond theoral cavity that are related to periodontal disease using the compositions containing lipoxin analogs, COX-2 inhibitors, or both.

Claims (61)

1. A method of treating a periodontal disease in a human or animal comprising administering to the human or animal a therapeutically effective amount of a composition comprising a compound which is a structural analog of lipoxin A 4 (LXA 4 ), lipoxin B 4 (LXB 4 ), 15-epi-lipoxin A 4 (15-epi-LXA 4 ) or 15-epi-lipoxin B 4 (15-epi-LXB 4 ).

2. The method according to claim 1 , wherein the compound is:

wherein R is selected from the group consisting of methyl and phenyl, Y is selected from the group consisting of oxygen and CH 2 , and n is 1 to 10.

3. The method according to claim 2 , wherein the compound is:

4. The method according to claim 1 , wherein the compound corresponds to any one of the formulae:

wherein:

R is selected from the group consisting of:

(i) hydrogen; and

(ii) straight, branched, cyclic, saturated, or unsaturated alkyl having from 1 to 20 carbon atoms;

R 1 , R 2 , R 12 , and R 13 are independently selected from the group consisting of:

(i) hydrogen;

(ii) straight, branched, cyclic, saturated, or unsaturated alkyl having from 1 to 20 carbon atoms;

(iii) substituted alkyl having from 1 to 20 carbon atoms, wherein the alkyl is substituted with one or more substituents selected from the group consisting of halo, hydroxy, lower alkoxy, aryloxy, amino, alkylamino, dialkylamino, acylamino, arylamino, hydroxyamino, alkoxyamino, alkylthio, arylthio, carboxy, carboxamido, carboalkoxy, aryl, and heteroaryl; substituted aryl or heteroaryl, wherein the aryl or heteroaryl is substituted with one or more substituents selected from the group consisting of alkyl, cycloalkyl, alkoxy, halo, aryl, heteroaryl, carboxyl, and carboxamido; and

(iv) a group Z-Y, wherein:

Z is selected from the group consisting of a straight, branched, cyclic, saturated, or unsaturated alkyl having from 1 to 20 carbon atoms; substituted lower alkyl, wherein the alkyl is substituted with one or more substituents selected from the group consisting of halo, hydroxy, lower alkoxy, aryloxy, amino, alkylamino, dialkylamino, acylamino, arylamino, hydroxyamino, alkoxyamino, alkylthio, arylthio, carboxy, carboxamido, carboalkoxy, aryl, and heteroaryl; and substituted aryl or heteroaryl, wherein the aryl or heteroaryl is substituted with one or more substituents selected from the group consisting of alkyl, cycloalkyl, alkoxy, halo, aryl, heteroaryl, carboxyl, and carboxamido; and

Y is selected from the group consisting of hydrogen; alkyl; cycloalkyl; carboxyl; carboxamido; aryl; heteroaryl; substituted aryl or heteroaryl, wherein the aryl or heteroaryl is substituted with one or more substituents selected from the group consisting of alkyl, cycloalkyl, alkoxy, halo, aryl, heteroaryl, carboxyl, and carboxamido;

R 3 selected from the group consisting of:

(i) hydrogen;

(ii) straight, branched, cyclic, saturated, or unsaturated alkyl having from 1 to 20 carbon atoms;

(iii) substituted alkyl having from 1 to 20 carbon atoms, wherein the alkyl is substituted with one or more sub stituents selected from the group consisting of halo, hydroxy, lower alkoxy, aryloxy, amino, alkylamino, dialkylamino, acylamino, arylamino, hydroxyamino, alkoxyamino, alkylthio, arylthio, carboxy, carboxamido, carboalkoxy, aryl, and heteroaryl; substituted aryl or heteroaryl, wherein the aryl or heteroaryl is substituted with one or more substituents selected from the group consisting of alkyl, cycloalkyl, alkoxy, halo, aryl, heteroaryl, carboxyl, and carboxamido; and

(iv) a group Z-Y, wherein:

Z is selected from the group consisting of a branched, cyclic, or unsaturated alkyl having from 1 to 20 carbon atoms; substituted lower alkyl, wherein the alkyl is substituted with one or more substituents selected from the group consisting of halo, hydroxy, lower alkoxy, aryloxy, amino, alkylamino, dialkylamino, acylamino, arylamino, hydroxyamino, alkoxyamino, alkylthio, arylthio, carboxy, carboxamido, carboalkoxy, aryl, and heteroaryl; and substituted aryl or heteroaryl, wherein the aryl or heteroaryl is substituted with one or more substituents selected from the group consisting of alkyl, cycloalkyl, alkoxy, halo, aryl, heteroaryl, carboxyl, and carboxamido; and

Y is selected from the group consisting of hydrogen; alkyl; cycloalkyl; carboxyl; carboxamido; aryl; heteroaryl; substituted aryl or heteroaryl, wherein the aryl or heteroaryl is substituted with one or more substituents selected from the group consisting of alkyl, cycloalkyl, alkoxy, halo, aryl, heteroaryl, carboxyl, and carboxamido; and

R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 and R 11 are independently selected from a group consisting of:

(i) hydrogen;

(ii) halo;

(iii) straight, branched, cyclic, saturated, or unsaturated alkyl having from 1 to 20 carbon atoms; and

(iv) substituted alkyl having from 1 to 20 carbon atoms, wherein the alkyl is substituted with one or more sub stituents selected from the group consisting of halo, hydroxy, lower alkoxy, aryloxy, amino, alkylamino, dialkylamino, acylamino, arylamino, hydroxyamino, alkoxyamino, alkylthio, arylthio, carboxy, carboxamido, carboalkoxy, aryl, and heteroaryl; substituted aryl or heteroaryl, wherein the aryl or heteroaryl is substituted with one or more substituents selected from the group consisting of alkyl, cycloalkyl, alkoxy, halo, aryl, heteroaryl, carboxyl, and carboxamido;

wherein, optionally, one or more pairs selected from R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 and R 13 are independently replaced with a bond that forms a carbon-carbon double bond, a carbon-carbon triple bond, or a ring with the lipoxin backbone optionally substituted with one or more halo, hydroxy, lower alkoxy, aryloxy, amino, alkylamino, dialkylamino, acylamino, arylamino, hydroxyamino, alkoxyamino, alkylthio, arylthio, carboxy, carboxamido, carboalkoxy, aryl or heteroaryl groups,

and wherein, optionally, one or more pairs selected from R, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 and R 13 are independently connected to form one or more rings containing 3 to 20 carbon atoms, wherein the rings optionally contain 1 to 6 oxygen atoms, 1 to 6 nitrogen atoms, or both 1 to 6 oxygen atoms and 1 to 6 nitrogen atoms, and wherein the rings are optionally substituted with one or more halo, hydroxy, lower alkoxy, aryloxy, amino, alkylamino, dialkylamino, acylamino, arylamino, hydroxyamino, alkoxyamino, alkylthio, arylthio, carboxy, carboxamido, carboalkoxy, aryl or heteroaryl groups.

5. The method according to claim 4 , wherein the compound is of the formula:

6. The method according to claim 5 , wherein the compound is:

wherein R is selected from the group consisting of methyl and phenyl, Y is selected from the group consisting of oxygen and CH 2 , and n is 1 to 10.

7. The method according to claim 6 , wherein the compound is:

8. The method according to claim 5 , wherein the compound is:

wherein R is selected from the group consisting of methyl and phenyl, and Y is selected from the group consisting of oxygen and CH 2 , and n is 1 to 10.

9. The method according to claim 4 , wherein the compound is of the formula

10. The method according to claim 9 , wherein the compound is:

wherein R is selected from the group consisting of methyl and phenyl, and Y is selected from the group consisting of oxygen and CH 2 , and n is 1 to 10.

11. The method according to claim 10 , wherein the compound is:

12. The method according to claim 4 , wherein the compound is of the formula:

13. The method according to claim 12 , wherein the compound is:

wherein R is selected from the group consisting of methyl and phenyl, and Y is selected from the group consisting of oxygen and CH 2 .

14. The method according to claim 1 , wherein the periodontal disease is gingivitis.

15. The method according to claim 1 , wherein the periodontal disease is periodontitis.

16. The method according to claim 1 , wherein the periodontal disease is aphthous ulcer.

17. The method according to claim 1 , wherein the periodontal disease is herpetic stomatitis.

18. The method according to claim 1 , wherein the administration is topical oral administration.

19. The method according to claim 1 , wherein the composition further comprises a COX-2 inhibitor.

20. The method according to claim 19 , wherein the COX-2 inhibitor is celecoxib, rofecoxib or valdecoxib.

21. The method according to claim 2 , wherein the compound is:

22. The method according to claim 2 , wherein the compound is:

wherein R is selected from the group consisting of methyl and phenyl.

23. The method according to claim 2 , wherein the compound is:

24. The method according to claim 6 , wherein the compound is:

25. The method according to claim 8 , wherein the compound is:

26. The method according to claim 13 , wherein the compound is:

wherein R is selected from the group consisting of methyl and phenyl.

27. The method according to claim 1 , wherein the compound is 15-R/S-methyl LXA 4 .

28. The method according to claim 1 , wherein the compound is 16-phenoxy LXA 4 .

29. A method of preventing a periodontal disease in a human or animal comprising administering to the human or animal a prophylactically effective amount of a composition comprising a compound which is a structural analog of lipoxin A 4 (LXA 4 ), lipoxin B 4 (LXB 4 ), 15-epi-lipoxin A 4 (15-epi-LXA 4 ) or 15-epi-lipoxin B 4 (1 5-epi-LXB 4 ).

Assignments (4)
A CORRECTIVE ASSIGNMENT TO CORRECT THE EXECUTION ON REEL 014765 FRAME 0571 Recorded Feb 22, 2005
From: VAN DYKE, THOMAS E.
To: TRUSTEES OF BOSTON UNIVERSITY
Reel/Frame 016294/0520 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 8, 2003
From: VAN DYKE, THOMAS E.
To: TRUSTEES OF BOSTON UNIVERSITY
Reel/Frame 014765/0571 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 8, 2003
From: SERHAN, CHARLES N.
To: BRIGHAM AND WOMEN'S HOSPITAL, INC.
Reel/Frame 014766/0132 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 8, 2003
From: PETASIS, NICOS A.
To: UNIVERSITY OF SOUTHERN CALIFORNIA
Reel/Frame 014787/0560 →